Lenvima (Lenvatinib)

Lenvima is a tyrosine kinase inhibitor used in oncology to target angiogenesis‑driven cancers.

• Differentiated thyroid cancer: improves progression‑free survival in patients with radioactive iodine‑refractory disease.
• Renal cell carcinoma: used in combination therapy to extend overall survival in advanced cases.
• Hepatocellular carcinoma: indicated for first‑line treatment of unresectable disease.

• Lenvatinib inhibits multiple receptor tyrosine kinases—including VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT—thereby blocking signaling pathways that promote tumor angiogenesis, cell proliferation and survival. By simultaneously targeting these receptors, the drug reduces new blood‑vessel formation and interferes with tumor growth and metastatic potential. The inhibition is dose‑dependent and results in decreased downstream activation of MAPK and PI3K‑AKT pathways, contributing to antitumor activity.

Lenvima may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypertension: elevated blood pressure often requiring medical management.
• Diarrhea: watery stools that may lead to dehydration.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of sickness that may reduce appetite.
• Proteinuria: presence of protein in urine indicating kidney involvement.
• Stomatitis: inflammation or ulceration of the mouth lining.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver enzyme elevations or liver failure.
• Cardiac failure: reduced heart function presenting with shortness of breath.
• Thromboembolic events: blood clots such as deep vein thrombosis or pulmonary embolism.

When prescribing Lenvima, clinicians should observe several precautionary measures to minimize risks.

• Monitor blood pressure: check regularly and treat hypertension promptly.
• Assess liver function: perform baseline and periodic liver enzyme tests.
• Evaluate cardiac status: conduct ECG and echocardiogram in patients with heart disease.
• Watch for proteinuria: test urine for protein during therapy.
• Adjust dose in renal impairment: consider reduced dosing for patients with decreased kidney function.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lenvima can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase Lenvatinib exposure and toxicity.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers: may reduce drug levels and effectiveness.
• Diuretics: can exacerbate hypertension or electrolyte disturbances.
• Hormonal contraceptives: may have reduced efficacy; consider alternative contraception.